Maze Therapeutics (MAZE) Treasury Shares (2024)
Maze Therapeutics (MAZE) posted Treasury Shares of $10372.0 for Q4 2025, down 98.26% sequentially from $594825.0 in Q3 2025, and down 100.0% YoY from $297.2 million in Q4 2024.
Powered by 
Analysis
Maze Therapeutics (MAZE) Treasury Shares (2024) Analysis & Trends
Maze Therapeutics has reported Treasury Shares for 2 years, with the latest figure at $10372.0 in Q4 2025.
- Quarterly Treasury Shares fell 100.0% year-over-year to $10372.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10372.0 (down 100.0% YoY) and the FY2025 annual result came in at $10372.0, down 100.0% from the prior year.
- Treasury Shares slipped to $10372.0 in Q4 2025 per MAZE's latest filing, from $594825.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $297.2 million in Q4 2024 and troughed at $10372.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 2.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Maze Therapeutics | 1.55 Bn | 1.55 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 297.21 Mn |
| Dec 31, 2024 | 297.21 Mn |
| Sep 30, 2024 | 203.42 Mn |
| Sep 30, 2024 | 203.42 Mn |
| Jun 30, 2024 | 203.42 Mn |
| Jun 30, 2024 | 203.42 Mn |
| Mar 31, 2024 | 203.42 Mn |
| Mar 31, 2024 | 203.42 Mn |